Method of measuring cell-substrate impedance in living cells to identify compounds affecting receptor tyrosine kinase (RTK) activity and pathways for the treatment of cancer
A method of identifying a therapeutic compound for treating cancer in a human subject, the method including: providing a device that measures cell-substrate impedance; culturing cancer cells in the at least two wells, wherein the cancer cells are obtained from a human subject and have a receptor tyrosine kinase (RTK) pathway; adding to a first well a proposed therapeutic compound that affects an RTK pathway and an RTK stimulating factor for the RTK pathway to form a test well, and adding to another well the RTK stimulating factor to form a control well; continuously monitoring cell-substrate impedance of the at least two wells; and determining a difference in impedance or optionally in cell index between the test well and control well; and if significantly different, concluding the proposed therapeutic compound is therapeutically active in the RTK pathway within the cancer cells of the human subject.
1. A method of identifying a therapeutic compound for treating cancer in a human subject, the method comprising:
a) providing a device that measures cell-substrate impedance, wherein the device comprises at least two wells, each well comprising an electrode array;
b) culturing cancer cells in the at least two wells, wherein the cancer cells are obtained from a human subject and comprise a receptor tyrosine kinase (RTK) pathway;
c) adding to a first well a proposed therapeutic compound that affects an RTK pathway and an RTK stimulating factor for the RTK pathway to form a test well, and adding to another well the RTK stimulating factor to form a control well;
d) continuously monitoring cell-substrate impedance of the at least two wells and optionally determining cell indices from the monitored cell-substrate impedance; and
e) determining a difference in impedance or optionally in cell index between the test well and control well; and if significantly different,
f) concluding the proposed therapeutic compound is therapeutically active in the RTK pathway within the cancer cells of the human subject, thereby identifying the proposed therapeutic compound as a therapeutic compound for treating cancer in the human subject.
2. The method of claim 1 , wherein the cancer cells are primary cells.
3. The method according to claim 1 , wherein the cancer cells are selected from the group consisting of breast cancer cells, lung cancer cells, and colon cancer cells.
4. The method according to claim 1 , wherein the cancer cells are selected from the group consisting of ovarian cancer cells, prostate cancer cells, hepatosarcoma cells, epidermoid cancer cells, and fibrosarcoma cells.
5. The method according to claim 1 , wherein the cancer cells are cultured in serum-free media.
6. The method of claim 1 , wherein the proposed therapeutic compound is a kinase inhibitor.
7. The method of claim 1 , wherein the proposed therapeutic compound is Trastuzumab or 4-Quinazolinamine N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholinyl) propoxy].
8. The method of claim 1 , wherein the proposed therapeutic compound is added before the RTK stimulating factor.
9. The method of claim 1 , wherein the RTK stimulating factor is a growth factor.
10. The method of claim 1 , wherein the RTK stimulating factor is selected from the group consisting of epidermal growth factor (EGF), platelet derived growth factor (PDGF), a nerve growth factor (NGF), hepatocyte growth factor (HGF), and fibroblast growth factor (FGF).
11. The method of claim 1 , wherein the method further comprises generating impedance-based curves for the at least two wells from the monitored impedance, wherein the impedance-based curves comprise monitored impedance values or cell index values.
12. The method of claim 11 , wherein the step of determining a difference in impedance or optionally in cell index between the test well and control well is performed by comparing the impedance-based curves between the test well and the control well.
13. The method of claim 1 , further comprising generating an impedance-based dose response curve of the proposed therapeutic compound.
14. The method of claim 13 , further comprising determining an EC50 or IC50 of the proposed therapeutic compound from the dose response curve.
15. The method of claim 1 , further comprising determining an IC50 of the proposed therapeutic compound.